Published in Oncology Business Week, July 16th, 2006
The company plans to use the funding to accelerate and expand the clinical program for its lead compound, BSI-201, and move two additional compounds toward clinical development.
"The additional funding will allow us to expand clinical development ahead of plan on our promising lead compound, BSI-201, while continuing to push our second clinical candidate toward its investigational new drug (IND) application with the Food and Drug Administration," said...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week